![](https://www.recercasantpau.cat/wp-content/uploads/2018/12/logo-nanoligent.png)
05/12/2018
Interview Valles Visio: Nanoligent
In June 2017, researchers from the IIB-Sant Pau, the Institute of Biotechnology and Biomedicine at the UAB and the CIBER-BBN, created a spin-off, Nanoligent, with the goal of developing the first drug...